Table 1

Total number of patients receiving functional MMR tumour testing, MLH1 promoter methylation testing and germline MMR gene testing in the endometrial cancer cohort

Number of tests			Test results
	Number	Per cent		Number	Per cent
Functional MMR tumour testing
Immunohistochemistry	1391	17.5	Abnormal	422	30.3
			Normal	966	69.4
			Failed/Unknown	3	0.2
Microsatellite instability	59	0.7	Abnormal	25	42.4
			MSI-high	23	39
			MSI-low	2	3.4
			Normal	34	57.6
MLH1 promoter methylation testing
MLH1 promoter methylation	173	2.2	Unmethylated (suggestive of LS)	23	13.3
			Methylated	146	84.4
			Failed/Unknown	4	2.3
Germline MMR gene testing
Germline MMR gene testing	76	1	Pathogenic/Likely pathogenic	23	30.3
			Variant of uncertain significance	4	5.3
			Likely benign/Benign/No variant	49	64.5

All tests and results for the cohort are counted, including those undertaken outside of the sequential three-step diagnostic testing pathway. For total tests in the cohort, percentages are presented as the number of tests/total cohort patients (7928). For test results, percentages are presented as result/number of patients tested.
LS, Lynch syndrome; MMR, mismatch repair; MSI, microsatellite instability.